Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Schenone

Showing results (141-150 of 173) with videos related to

Pageof 18
Sort By:
Chemmedchem|July 2, 2013
Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agentsCristina Tintori, Ilaria Laurenzana, Francesco La Rocca, et al.
Chemmedchem|March 14, 2008
Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor modelTiziano Tuccinardi, Silvia Schenone, Francesco Bondavalli, et al.
Chemmedchem|February 26, 2013
A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitorsMattia Mori, Cristina Tintori, Robert Selwyne Arul Christopher, et al.
Journal of Medicinal Chemistry|October 18, 2002
Synthesis, molecular modeling studies, and pharmacological activity of selective A(1) receptor antagonistsFrancesco Bondavalli, Maurizio Botta, Olga Bruno, et al.
Journal of Medicinal Chemistry|February 9, 2008
Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell linesFabrizio Manetti, Chiara Brullo, Matteo Magnani, et al.
European Journal of Medicinal Chemistry|August 11, 2019
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell linesAnna Lucia Fallacara, Raffaele Passannanti, Mattia Mori, et al.
European Journal of Medicinal Chemistry|October 15, 2024
Applying molecular hybridization to design a new class of pyrazolo[3,4-d]pyrimidines as Src inhibitors active in hepatocellular carcinomaSalvatore Di Maria, Raffaele Passannanti, Federica Poggialini, et al.
Translational Oncology|June 5, 2019
In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug SensitivityLucia D'Antona, Vincenzo Dattilo, Giada Catalogna, et al.
Journal of Medicinal Chemistry|March 30, 2011
Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization studyMarco Radi, Elena Dreassi, Chiara Brullo, et al.
Drug Development Research|February 13, 2024
Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatmentChiara Vagaggini, Debora Petroni, Ilaria D'Agostino, et al.
Pageof 18

Showing results (141-150 of 173) with videos related to

Sort By:
Pageof 18
Chemmedchem|July 2, 2013
Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agentsCristina Tintori, Ilaria Laurenzana, Francesco La Rocca, et al.
Chemmedchem|March 14, 2008
Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor modelTiziano Tuccinardi, Silvia Schenone, Francesco Bondavalli, et al.
Chemmedchem|February 26, 2013
A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitorsMattia Mori, Cristina Tintori, Robert Selwyne Arul Christopher, et al.
Journal of Medicinal Chemistry|October 18, 2002
Synthesis, molecular modeling studies, and pharmacological activity of selective A(1) receptor antagonistsFrancesco Bondavalli, Maurizio Botta, Olga Bruno, et al.
Journal of Medicinal Chemistry|February 9, 2008
Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell linesFabrizio Manetti, Chiara Brullo, Matteo Magnani, et al.
European Journal of Medicinal Chemistry|August 11, 2019
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell linesAnna Lucia Fallacara, Raffaele Passannanti, Mattia Mori, et al.
European Journal of Medicinal Chemistry|October 15, 2024
Applying molecular hybridization to design a new class of pyrazolo[3,4-d]pyrimidines as Src inhibitors active in hepatocellular carcinomaSalvatore Di Maria, Raffaele Passannanti, Federica Poggialini, et al.
Translational Oncology|June 5, 2019
In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug SensitivityLucia D'Antona, Vincenzo Dattilo, Giada Catalogna, et al.
Journal of Medicinal Chemistry|March 30, 2011
Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization studyMarco Radi, Elena Dreassi, Chiara Brullo, et al.
Drug Development Research|February 13, 2024
Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatmentChiara Vagaggini, Debora Petroni, Ilaria D'Agostino, et al.
Pageof 18